

# David J Kerr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1346621/publications.pdf>

Version: 2024-02-01

108  
papers

12,834  
citations

46918

47  
h-index

33814

99  
g-index

109  
all docs

109  
docs citations

109  
times ranked

16141  
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management. <i>Familial Cancer</i> , 2022, 21, 197-209.	0.9	31
2	The Essentials of Multiomics. <i>Oncologist</i> , 2022, 27, 272-284.	1.9	11
3	Genetic variation in <i>ST6GAL1</i> is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. <i>International Journal of Cancer</i> , 2022, , .	2.3	3
4	Cancer in sub-Saharan Africa: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2022, 23, e251-e312.	5.1	94
5	Designing deep learning studies in cancer diagnostics. <i>Nature Reviews Cancer</i> , 2021, 21, 199-211.	12.8	175
6	Cancer and COVID-19 Experiences at African Cancer Centers: The Silver Lining. <i>JCO Global Oncology</i> , 2021, 7, 410-415.	0.8	7
7	Celecoxib for Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1257.	3.8	9
8	Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. <i>International Journal of Cancer</i> , 2021, 149, 1713-1722.	2.3	7
9	Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer. <i>Lancet Oncology</i> , The, 2021, 22, e358-e368.	5.1	133
10	Stromal composition predicts recurrence of early rectal cancer after local excision. <i>Histopathology</i> , 2021, 79, 947-956.	1.6	8
11	Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer. <i>EBioMedicine</i> , 2021, 71, 103547.	2.7	4
12	Personalising cancer medicine with prognostic markers. <i>EBioMedicine</i> , 2021, 72, 103577.	2.7	9
13	Biomarkers in oncology. , 2021, , 195-202.		0
14	Virtual Oncology in the Time of COVID-19 Pandemic: Moving Forward!. <i>Innovations in Digital Health Diagnostics and Biomarkers</i> , 2021, 1, 19-20.	0.5	0
15	The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. <i>Oncologist</i> , 2020, 25, e1-e4.	1.9	9
16	The Oncology Data Network ( ODN ): Methodology, Challenges, and Achievements. <i>Oncologist</i> , 2020, 25, e1428-e1432.	1.9	3
17	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020, 46, 955-966.	0.5	22
18	Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. <i>Lancet</i> , The, 2020, 395, 350-360.	6.3	364

#	ARTICLE	IF	CITATIONS
19	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. <i>British Journal of Cancer</i> , 2019, 121, 474-482.	2.9	41
20	Confirmation that somatic mutations of beta $\alpha$ 2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial. <i>Histopathology</i> , 2019, 75, 236-246.	1.6	15
21	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. <i>Nature Communications</i> , 2019, 10, 2154.	5.8	172
22	Challenges and solutions in patient treatment strategies for stage II colon cancer. <i>Gastroenterology Report</i> , 2019, 7, 151-161.	0.6	41
23	An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. <i>Oncogenesis</i> , 2019, 8, 13.	2.1	99
24	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. <i>International Journal of Cancer</i> , 2019, 144, 2161-2168.	2.3	34
25	The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial. <i>Journal of Surgical Oncology</i> , 2018, 117, 1043-1048.	0.8	10
26	Chromatin organisation and cancer prognosis: a pan-cancer study. <i>Lancet Oncology</i> , The, 2018, 19, 356-369.	5.1	67
27	Prognostic markers for colorectal cancer: estimating ploidy and stroma. <i>Annals of Oncology</i> , 2018, 29, 616-623.	0.6	56
28	Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil results from the QUASAR trial of colorectal cancer. <i>Histopathology</i> , 2018, 72, 391-404.	1.6	16
29	Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci. <i>International Journal of Cancer</i> , 2018, 142, 540-546.	2.3	26
30	Facing the Global Challenges of Access to Cancer Medication. <i>Journal of Global Oncology</i> , 2018, 4, 1-7.	0.5	3
31	Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia. <i>Journal of Global Oncology</i> , 2018, 4, 1-4.	0.5	6
32	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 635-643.	3.7	60
33	Donors, Noncommunicable Diseases, and Universal Health Coverage to High-quality Healthcare: An Opportunity for Action on Global Functions for Health. <i>Journal of Epidemiology and Global Health</i> , 2018, 8, 236.	1.1	0
34	Whole-genome sequencing identifies homozygous <i>BRCA2</i> deletion guiding treatment in dedifferentiated prostate cancer. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001362.	0.5	9
35	Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. <i>International Journal of Cancer</i> , 2017, 140, 2701-2708.	2.3	76
36	Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis. <i>European Journal of Cancer</i> , 2017, 84, 228-238.	1.3	81

#	ARTICLE	IF	CITATIONS
37	Multilevel genomics of colorectal cancers with microsatellite instabilityâ€™ clinical impact of JAK1 mutations and consensus molecular subtype 1. <i>Genome Medicine</i> , 2017, 9, 46.	3.6	71
38	How Useful Are International Treatment Guidelines in Low- and Middle-Income Countries?. <i>Journal of Global Oncology</i> , 2017, 3, 441-443.	0.5	16
39	Strategies for Sustainable Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e11-e15.	1.8	6
40	Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 266-272.	2.9	57
41	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216.	3.7	227
42	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1543-1557.	5.1	129
43	Is sidedness prognostically important across all stages of colorectal cancer?. <i>Lancet Oncology</i> , The, 2016, 17, 1480-1482.	5.1	15
44	Addressing unwarranted variations in colorectal cancer outcomes: a conceptual approach. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 706-712.	12.5	10
45	<scp>HER2</scp> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <scp>QUASAR</scp>, <scp>FOCUS</scp> and <scp>PICCOLO</scp> colorectal cancer trials. <i>Journal of Pathology</i> , 2016, 238, 562-570.	2.1	185
46	Variation at 2q35 (<i>PNKD</i> and <i>TMBIM1</i>) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease. <i>Human Molecular Genetics</i> , 2016, 25, 2349-2359.	1.4	37
47	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 1182-1189.	0.8	32
48	Should We Adapt Existing Quality Systems for Use in Low- and Middle-Income Countries?. <i>Journal of Oncology Practice</i> , 2015, 11, 370-371.	2.5	3
49	A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. <i>Scientific Reports</i> , 2015, 5, 10442.	1.6	109
50	Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in <i>CDH1</i> Is a Prognostic Marker of Survival. <i>Clinical Cancer Research</i> , 2015, 21, 3453-3461.	3.2	24
51	Biomarkers in Oncology. , 2015, , 185-188.		0
52	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYD and a putative role forENOSF1 rather thanTYMS. <i>Gut</i> , 2015, 64, 111-120.	6.1	93
53	Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer. <i>Oncoscience</i> , 2015, 2, 508-516.	0.9	11
54	Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial. <i>Anticancer Research</i> , 2015, 35, 1641-5.	0.5	9

#	ARTICLE	IF	CITATIONS
55	EU data protection regulationâ€™harming cancer research. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 563-564.	12.5	5
56	Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 363-371.	1.0	4
57	Building capacity for sustainable research programmes for cancer in Africa. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 251-259.	12.5	68
58	'Toxgnostics': an unmet need in cancer medicine. <i>Nature Reviews Cancer</i> , 2014, 14, 440-445.	12.8	29
59	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1031-1039.	0.8	216
60	Clinical cancer research: the past, present and the future. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 663-669.	12.5	29
61	Toxgnostics: predicting and preventing chemotherapy-induced side effects. <i>Personalized Medicine</i> , 2014, 11, 683-685.	0.8	1
62	Evaluation of <i>PIK3CA</i> Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4297-4305.	0.8	181
63	Tailoring treatment and trials to prognosis. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 429-430.	12.5	5
64	Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. <i>Journal of Pathology</i> , 2013, 229, 441-448.	2.1	80
65	Germline mutations affecting the proofreading domains of <i>POLE</i> and <i>POLD1</i> predispose to colorectal adenomas and carcinomas. <i>Nature Genetics</i> , 2013, 45, 136-144.	9.4	851
66	The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database. <i>Clinical Colorectal Cancer</i> , 2013, 12, 179-187.	1.0	27
67	Stage II colon cancer. <i>Chinese Clinical Oncology</i> , 2013, 2, 16.	0.4	7
68	Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer. <i>Journal of Human Genetics</i> , 2012, 57, 709-716.	1.1	9
69	Common variation near <i>CDKN1A</i> , <i>POLD3</i> and <i>SHROOM2</i> influences colorectal cancer risk. <i>Nature Genetics</i> , 2012, 44, 770-776.	9.4	210
70	Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN. <i>Oncotarget</i> , 2012, 3, 1348-1355.	0.8	54
71	Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 17-24.	0.8	487
72	Value of Mismatch Repair, <i>KRAS</i> , and <i>BRAF</i> Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1261-1270.	0.8	593

#	ARTICLE	IF	CITATIONS
73	Predictive biomarkers: a paradigm shift towards personalized cancer medicine. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 587-596.	12.5	259
74	Bevacizumabâ€”has it reached its final resting place?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 195-196.	12.5	10
75	Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal cancer patients. <i>Journal of Human Genetics</i> , 2011, 56, 58-63.	1.1	9
76	Validation Study of a Quantitative Multigene Reverse Transcriptaseâ€”Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4611-4619.	0.8	341
77	Better value cancer care for the 21st century. <i>Annals of Oncology</i> , 2011, 22, 2541-2545.	0.6	1
78	Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer. <i>PLoS Genetics</i> , 2011, 7, e1002105.	1.5	188
79	QUASAR Results: The Prognostic Validity of a Colon Cancer Recurrence Score and the Role of Multigene Profiles in Determining Risk. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 144-147.	1.0	4
80	Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. <i>Nature Genetics</i> , 2010, 42, 973-977.	9.4	335
81	Defective Mismatch Repair in Colon Cancer: A Prognostic Or Predictive Biomarker?. <i>Journal of Clinical Oncology</i> , 2010, 28, 3210-3212.	0.8	29
82	Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4575-4580.	0.8	81
83	Can We Treat Cancer for a Dollar a Day? Guidelines for Low-Income Countries. <i>New England Journal of Medicine</i> , 2010, 363, 801-803.	13.9	65
84	British Lessons on Health Care Reform. <i>New England Journal of Medicine</i> , 2009, 361, e21.	13.9	16
85	Open access chemical and clinical probes to support drug discovery. <i>Nature Chemical Biology</i> , 2009, 5, 436-440.	3.9	122
86	Genetic prognostic and predictive markers in colorectal cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 489-499.	12.8	602
87	Cetuximab plus chemotherapy in patients with advanced NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 499-500.	12.5	5
88	A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. <i>Nature Genetics</i> , 2008, 40, 623-630.	9.4	514
89	Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. <i>Nature Genetics</i> , 2008, 40, 26-28.	9.4	277
90	Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. <i>Nature Genetics</i> , 2008, 40, 1426-1435.	9.4	498

#	ARTICLE	IF	CITATIONS
91	Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 250-251.	4.3	1
92	Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 360-369.	13.9	124
93	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4569-4574.	0.8	220
94	Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. <i>Lancet</i> , The, 2007, 370, 2020-2029.	6.3	1,244
95	A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. <i>Nature Genetics</i> , 2007, 39, 1315-1317.	9.4	463
96	A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. <i>Nature Genetics</i> , 2007, 39, 984-988.	9.4	754
97	Today's Science, Tomorrow's Patient: the Pivotal Role of Tissue, Clinical Data and Informatics in Modern Drug Development. , 2006, , 185-209.		0
98	Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 480-481.	4.3	0
99	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 8664-8670.	0.8	607
100	Targeting angiogenesis in cancer: clinical development of bevacizumab. <i>Nature Clinical Practice Oncology</i> , 2004, 1, 39-43.	4.3	85
101	Two errors. <i>Lancet</i> , The, 2004, 364, 907.	6.3	0
102	Clinical development of gene therapy for colorectal cancer. <i>Nature Reviews Cancer</i> , 2003, 3, 615-622.	12.8	84
103	A Trial of Adjuvant Therapy in Colorectal Cancer: The VICTOR Trial. <i>Clinical Colorectal Cancer</i> , 2003, 3, 58-60.	1.0	14
104	Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. <i>Lancet</i> , The, 2003, 361, 368-373.	6.3	233
105	NTRAC pioneering a virtual model. <i>Lancet Oncology</i> , The, 2003, 4, 393.	5.1	2
106	Redesigning cancer care. <i>BMJ: British Medical Journal</i> , 2002, 324, 164-166.	2.4	52
107	Capecitabine/irinotecan combination regimens in colorectal cancer. <i>Oncology</i> , 2002, 16, 27-9.	0.4	0
108	Developing a Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction. , 0, , 691-710.		0